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Venous thromboembolism, designating deep vein throm-bosis (DVT) together with pulmonary embolism (PE), is 
a severe disease frequently diagnosed in the Western world. 
This pathological condition develops in ≈100 to 200 per 
100 000 individuals annually.1 In a part of patients (≈69 per 
100 000),2 DVT is complicated by PE, in which blood clot de-
taches and reaches lungs, leading to death in ≈30% of cases.3 
As per estimation of the American Surgeon General, these dis-
eases are responsible for >100 000 deaths a year in the United 
States only,4 exceeding mortality after myocardium infarction 
or stroke.5 Even after successful treatment, DVT and PE may 
result in post-thrombotic syndrome and chronic thromboem-
bolic pulmonary hypertension, respectively,6,7 causing poor 
life quality and requiring additional medical attention, includ-
ing prolonged period of anticoagulation therapy.
Editorial, see p 899 
Meet the First Author, see p 894
Mechanisms of thrombus development in veins remain 
incompletely understood. Risk factors for DVT include those 
that cannot be avoided or changed (such as old age or cancer) 
and various medical conditions, such as obesity, hypertension, 
and atrial fibrillation.8,9 About 60% of patients, who develop 
DVT and PE after hospitalization or surgery, develop the dis-
ease within 90 days,8 demonstrating connection between pre-
vious invasive therapy and DVT formation.
From the pathogenetic point of view, factors triggering throm-
bosis in veins differ from those in arteries. Arterial thrombosis usu-
ally starts with atherosclerotic plaque rupture with exposure of the 
subendothelial adhesive proteins, to which platelets bind forming 
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Rationale: Deep vein thrombosis (DVT) and its complication pulmonary embolism have high morbidity reducing 
quality of life and leading to death. Cellular mechanisms of DVT initiation remain poorly understood.
Objective: We sought to determine the role of mast cells (MCs) in DVT initiation and validate MCs as a potential 
target for DVT prevention.
Methods and Results: In a mouse model, DVT was induced by partial ligation (stenosis) of the inferior vena cava. 
We demonstrated that 2 strains of mice deficient for MCs were completely protected from DVT. Adoptive transfer 
of in vitro differentiated MCs restored thrombosis. MCs were present in the venous wall, and the number of 
granule-containing MCs decreased with thrombosis. Pharmacological depletion of MCs granules or prevention of 
MC degranulation also reduced DVT. Basal plasma levels of von Willebrand factor and recruitment of platelets to 
the inferior vena cava wall after DVT induction were reduced in MC-deficient mice. Stenosis application increased 
plasma levels of soluble P-selectin in wild-type but not in MC-deficient mice. MC releasate elevated ICAM-1 
(intercellular adhesion molecule-1) expression on HUVEC (human umbilical vein endothelial cells) in vitro. 
Topical application of compound 48/80, an MC secretagogue, or histamine, a Weibel–Palade body secretagogue 
from MCs, potentiated DVT in wild-type mice, and histamine restored thrombosis in MC-deficient animals.
Conclusions: MCs exacerbate DVT likely through endothelial activation and Weibel–Palade body release, which 
is, at least in part, mediated by histamine. Because MCs do not directly contribute to normal hemostasis, they can 
be considered potential targets for prevention of DVT in humans.  (Circ Res. 2017;121:941-950. DOI: 10.1161/
CIRCRESAHA.117.311185.)
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a relatively small platelet-rich thrombus. In contrast, in veins, large 
thrombi enriched by red blood cells develop without signs of en-
dothelial denudation.10 DVT begins in venous valvular sinus, in 
which blood flow can become stagnant resulting in prolonged time 
of blood exchange in valves, or stasis, an element of the Virchow 
triad.11 In venous valves, hypoxia and elevated hematocrit have 
been observed, which may increase local thombogenicity.12 The 
role of blood flow stagnancy increases in people in bed-ridden po-
sition caused by surgery or other situations accompanied by total or 
partial immobilization (limb paralysis, long-haul flights, etc).
We and others have demonstrated that an inflammatory 
component plays a role in triggering DVT.13,14 Local hypoxia 
may result in release of Weibel–Palade body (WPB) constitu-
ents, such as von Willebrand factor (vWF) and P-selectin, to 
the endothelial surface leading to recruitment of platelets and 
leukocytes.15 Platelets can contribute to thrombosis initiation 
likely by providing their procoagulant surface to clotting fac-
tors, whereas neutrophils support DVT propagation by pro-
ducing neutrophil extracellular traps.16,17
Mast cells (MCs) are a part of the innate immune system. 
They originate from the hematopoietic progenitor in bone mar-
row and enter the circulation as early lineage progenitors.18 After 
egression to tissues and maturation, MCs express a specific set 
of antigens including FcεRI (a receptor for immunoglobulin E) 
and Kit (a receptor for stem cell factor). The role of MCs in al-
lergic inflammation, a risk factor for DVT and PE,19 has been 
well documented.20 MC granules contain potent anticoagulants, 
such as heparin and tPA (tissue-type plasminogen activator); 
endothelial activators (histamine and tumor necrosis factor-α); 
and many enzymes (tryptases, chymases, and others).21,22 In tis-
sues, MCs are located in the vicinity of blood vessels,23 and 
their presence at the site of human DVT has been reported.24
Herein, using murine models, we demonstrate that libera-
tion of MC granule constituents is critical for DVT initiation. 
This is a novel mechanism regulating venous thrombosis, 
which could potentially be used to target DVT in humans.
Methods
Animals
MC-deficient KitW-v (Jackson Laboratory 000049, backcrossed to 
C57BL/6J for decades) mice25 and KitW-sh (Jackson Laboratory 012861, 
backcrossed to C57BL/6J for 11 generations) mice26,27 were purchased 
in the Jackson Laboratory, and colonies were maintained in animal fa-
cilities at Children’s Hospital Boston and the University of Birmingham 
under standard conditions. Wild-type littermates were used as a control 
in DVT and intravital microscopy experiments. C57BL/6 mice from 
Charles River were used in experiments with topical application of his-
tamine and compound 48/80. All animal experiments were approved 
by either Institutional Animal Review Board at Children’s Hospital 
Boston or Animal Welfare Ethical Review Body and the UK Home 
Office (United Kingdom; Project Licenses 40/3745 and 70/8286).
DVT Surgery
The stenosis of the inferior vena cava (IVC) was performed as de-
scribed previously.13 In brief, mice were anesthetized with isoflurane–
oxygen mixture, midabdominal incision was performed, and intestines 
were exteriorized and soaked in warm saline. All the IVC side branch-
es were ligated. The IVC was gently isolated from aorta, a 7-0 poly-
propylene suture was placed over the IVC, and ligated over a spacer 
(30-gauge needle), and then, the spacer was removed. This method 
produces IVC lumen area reduction by ≈90% and is not accompanied 
by endothelial denudation. Finally, peritoneum was closed with silk 
suture and skin with either suture or staples. Thrombosis was evalu-
ated at different time points ≤48 hours, and thrombi were excised for 
measurement. Assessment of thrombus weight and length by scale and 
ruler, respectively, has certain limitations; for example, precision of 
length measurement is ≈0.5 mm, whereas weight determination may 
vary ±1 to 1.5 mg. However, area of thrombi measured by ultrasonog-
raphy and thrombus weight determined by scale demonstrate strong 
correlation (r2=0.96)28; and therefore, the manual method of thrombus 
size assessment used in this study can be considered valid.
Nonstandard Abbreviations and Acronyms
DVT deep vein thrombosis
FcεRI immunoglobulin E receptor I
IVC inferior vena cava
MC mast cells
PE pulmonary embolism
vWF von Willebrand Factor
WPB Weibel–Palade body
WT wild type
Novelty and Significance
What Is Known?
• Development of deep vein thrombosis (DVT) includes mechanisms 
similar to sterile inflammation.
• Mast cells (MCs) reside in the vicinity to blood vessels.
• MCs contain granular mediators affecting both thrombosis and 
inflammation.
What New Information Does This Article Contribute?
• MC granular constituents promote DVT in mice.
• Genetic depletion or pharmacological inhibition of MC granule release 
protects mice from DVT.
• Targeting MCs may be a safe and efficient strategy to prevent DVT.
Current methods of DVT prophylaxis are usually based on inhi-
bition of blood coagulation factors. Because these factors are 
involved in normal bleeding arrest, such strategy results in bleed-
ing complications in a part of patients, and, therefore, new ap-
proaches are required. We demonstrated that MCs induce DVT 
in a mouse model. Mice lacking MCs were protected against 
DVT. Pharmacological ablation of MCs or inhibition of their de-
granulation also prevented venous thrombosis. Local stimulation 
of MC degranulation or release of Weibel–Palade bodies from 
endothelial cells strongly promoted DVT. These findings suggest 
that proinflammatory mediators released from MC granules are 
able to cause DVT. Given that MC deficiency is not accompanied 
by impaired hemostasis and therefore unlikely to provoke bleed-
ing complications, MCs may be a target for DVT prophylaxis in 
humans.
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Culture of Murine Bone Marrow–Derived MCs
Bone marrow–derived MC culture was established as described else-
where.29 In brief, bone marrow cells were flushed from adult wild-type 
(WT) mice femurs and tibia, centrifuged, and resuspended in RPMI 
(Roswell Park Memorial Institute) medium containing 10% fetal bo-
vine serum, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 25 mmol/L 
HEPES, 2 mmol/L l-glutamine, 1 mmol/L sodium pyruvate, 1 mmol/L 
nonessential amino acids, and 1 mmol/L MEM (minimal essential me-
dium) amino acids (all from Sigma) in the presence of 5 ng/mL recom-
binant mouse interleukin-3 (Peprotech). A selection process for mature 
MCs was for a period of at least 4 weeks with continuous enrichment 
for nonadherent fraction of MC precursors. After this period, cells were 
phenotypically >90% mature as assessed by fluorescence-activated 
cell sorter staining with antibodies against mouse FcεR1-PE (eBiosci-
ence; clone MAR-1) and CD117(c-Kit)-APC (eBioscience; clone 2B8; 
Online Figure I). To induce MC degranulation, cells were sensitized 
overnight with 100 ng/mL mouse anti-DNP-IgE (Sigma), washed, and 
stimulated with 100 ng/mL DNP-HSA (dinitrophenyl-human serum al-
bumin; Sigma) for 0.5 or 1 hour (fast release) or 6 hours (slow release). 
The efficiency of mediator release was monitored by β-hexaminidase 
activity in MC supernatants (releasates; Online Figure I).30
MC Granule Depletion
Mice were pretreated IP every 12 hours for 4 days with the MC-
degranulating compound 48/80 dissolved in 200 μL of sterile saline 
according to the following scheme: first day, 0.6 mg/kg; second day, 
1.0 mg/kg; third day, 1.2 mg/kg; fourth day, 2.4 mg/kg. This treat-
ment results in peritoneal MC granule content depletion by ≈84%.31 
Twenty-four hours after last injection, mice were subjected to IVC 
stenosis for 48 hours.
MC Membrane Stabilization In Vivo
MC membrane stabilizer sodium cromoglycate (cromolyn, 
100 mg/kg body weight; Sigma) or 200 µL of sterile saline was in-
jected IP into mice 24 hours and 30 minutes before surgery. Then, 
IVC stenosis was applied for 48 hours. Ketotifen (25 mg/kg body 
weight; Sigma) or 200 µL of sterile saline was injected IP 24 hours 
and 30 minutes before and 24 hours after IVC stenosis applica-
tion for 48 hours. Sodium cromoglycate inhibits MC degranulation 
and has previously been shown to work in mice in the indicated or 
lower dose.32,33
Murine Doppler Ultrasound
Doppler ultrasound was performed as described previously.34,35 Mice 
were anesthetized with isoflurane 2% plus oxygen, the region of in-
terest was shaved, and covered with ultrasound gel. Images of the 
vena cava inferior and surrounding structures and vessels were ob-
tained using the Visualsonics Vevo 2100 system with a cardiovascular 
scanhead.
Determination of Plasma vWF Levels
The test was performed as described previously.13 The level of vWF 
in pooled plasma of 20 C57BL/6 mice served as a control.
Results
MC-Deficient Mice Are Protected Against DVT
To clarify whether MCs play a role in DVT, we subjected mice 
with W-sh Kit mutation, which lack MCs, to IVC stenosis. 
Both 24 and 48 hours after stenosis application, none of the 
mutant mice developed a thrombus compared with 75% and 
90% thrombosis in WT controls, respectively (Figure 1A and 
1B). To confirm the phenotype, we used another strain of Kit 
mutants, KitW-v, with littermate controls. After 48-hour stenosis, 
89% of control mice developed a thrombus, whereas no throm-
bosis was observed in KitW-v animals (Figure 1C). Further ex-
periments were performed using KitW-sh mutants with littermate 
controls. To verify presence of thrombi in WT and absence in 
KitW-sh mice by an independent method, we used ultrasound 
Doppler (Figure 1D). Control WT mice with a thrombus did 
not have blood flow in the IVC and their IVC could not be 
compressed by applying pressure on the mouse abdomen with 
the probe. In contrast, KitW-sh mice had clear blood flow in the 
IVC, and the IVC was easily compressible suggesting absence 
of thrombi. The protective effect of MC deficiency was spe-
cific to DVT because no difference in thrombosis between 
WT and KitW-sh mice in ferric chloride–induced thrombosis 
was observed (Online Figure IIA). This finding indicates that 
the prothrombotic effect of MCs requires endothelial mono-
layer, which is denuded by ferric chloride.36 Tail bleeding time 
and coagulation tests (prothrombin time and activated partial 
thromboplastin time) in KitW-sh mice were unchanged com-
pared with WT controls (Online Figure IIB through IID).
MC Reconstitution Restores Thrombosis in MC-
Deficient Mice
In addition to the absence of MCs, Kit mutation mediates 
other abnormalities, such as defective melanogenesis and 
impaired germ cell development. To rule out any other po-
tential mechanisms, through which mutant Kit could affect 
thrombosis, we performed adoptive transfer of in vitro differ-
entiated bone marrow MCs to KitW-sh mice, a procedure that 
restores MC pool in murine tissues.37,38 About 8 to 10 weeks 
after adoptive transfer, mice were subjected to IVC stenosis. 
As seen in Figure 1B, 67% of these animals produced a throm-
bus, which was significantly higher than MC-deficient mice 
without adoptive transfer and did not differ from thrombosis 
prevalence in WT controls. Thrombus weight and length in 
KitW-sh mice with and without adoptive transfer were also sig-
nificantly different. Thus, it is the lack of MCs that protects 
against DVT.
Granule-Containing MCs Are Present in the 
IVC Wall and Their Number Decreases With 
Thrombosis
To test MC availability in the IVC, we performed staining 
of the vessel wall with Toluidine blue, a dye that specifically 
stains MC granules. MCs were found in the IVC wall in the 
vicinity to the abluminal side of the endothelium (Figure 2A). 
Forty-eight hours after stenosis application, the number of 
MCs in the IVC wall 2 to 3 mm below the ligation decreased 
in mice that developed thrombi compared with sham-operated 
animals (12.1±1.0 versus 25.6±2.1; P<0.0001; Figure 2B; 
Online Figure III). This result suggests that in the course of 
DVT, MCs either migrate out of the vessel wall or degranulate 
and thus lose Toluidine blue granule staining. The number of 
MCs in the IVCs of mice after 48-hour stenosis but without 
thrombi remained unchanged (33.4±8.1; P=0.27). This find-
ing implies that degranulation of MCs in the IVC wall is as-
sociated with thrombosis.
MC Granule Depletion Prevents DVT
We next assessed whether pharmacological ablation of MCs 
phenocopy the absence of DVT in KitW-sh mice. MC granules 
were depleted by consecutive daily injections of compound 
48/80 as described in Methods section. Thrombi developed 
in 86% of control saline-treated mice, whereas none of the 
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Figure 1. KitW-sh and KitW-v mice are protected against deep vein thrombosis, and mast cell (MC) repopulation restores thrombosis. 
KitW-sh mice and wild-type (WT) littermates were subjected to 24 h (A) or 48 h (B and C) stenosis of the inferior vena cava (IVC). A separate 
group of KitW-sh mice (n=9) had undergone adoptive transfer (AT) of 10×106 in vitro differentiated MCs 3 mo before the experiment. 
A, WT, n=8; KitW-sh, n=6. B, WT, n=10; KitW-sh, n=14, KitW-sh+AT, n=9. C, KitW-v mice (n=8) and WT littermates (n=9) underwent 48 h of the 
IVC stenosis. Presented are thrombus weight (i), thrombus length (ii), and thrombosis prevalence (iii). Note absence of thrombosis in 
both strains of MC-deficient mice and restoration of thrombosis after the adoptive transfer. D, WT (i) or a KitW-sh (ii) mice underwent IVC 
stenosis for 48 h, and then, thrombus formation was analyzed by Doppler ultrasound. Note lack of flow in the IVC of the WT mouse and 
presence of flow in the IVC of the MC-deficient mouse. (iii) Comparison of thrombosis prevalence between WT and MC-deficient mice 
analyzed by ultrasound.
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mice administered with compound 48/80 had a thrombus 
(Figure 3). This result implied that functional MCs are critical 
for venous thrombosis.
Lack of MCs Is Accompanied by Suppressed 
Endothelial Activation
We have previously reported the key role of endothelial acti-
vation and secretion of WPB constituents for DVT initiation 
in mice.13 Because mice lacking MCs are protected against 
DVT, we next tested whether MCs regulate activation of the 
endothelium. Unchallenged Kitw-sh mice had lower plasma lev-
els of vWF (Figure 4A), suggesting an association between 
presence or absence of MCs and circulating levels of vWF 
under quiescent conditions. Stenosis of the IVC promotes 
cell recruitment, which is a prerequisite to thrombus devel-
opment.13,17 Therefore, we next tested whether this process 
is modified in the absence of MCs. Using intravital micros-
copy, we demonstrated that in WT mice 6 hours after stenosis 
application, multiple platelets stay adherent to the IVC wall 
(Figure 4B; Online Movie I). In contrast, in MC-null mice, 
only single platelets were adhered with majority of the cells 
moving with blood flow without detectable contact with the 
endothelium (Figure 4B; Online Movie II). The area cov-
ered by adhered platelets was 6.9±0.73% in WT mice versus 
2.4±0.54% in KitW-sh animals (P<0.003; Figure 4C). This re-
sult suggests that MCs are implicated in endothelial activa-
tion preceding DVT. MC releasate was also able to stimulate 
expression of ICAM-1 (intercellular adhesion molecule-1) on 
HUVECs (human umbilical vein endothelial cells) in vitro 
(Online Figure IV), which is involved in leukocyte accumula-
tion near the vessel wall. In addition, stenosis induced eleva-
tion in plasma levels of sP-selectin, a biomarker of venous 
thrombosis both in experimental animals and patients,17,39–42 
in control but not in KitW-sh mice (Online Figure V). Thus, MC 
deficiency results in suppressed cell recruitment to the vas-
cular wall at early stages of DVT, potentially because of im-
paired release of adhesive substances from the endothelium.
Prevention of MC Degranulation Is Protective 
Against DVT
MCs fulfill their biological functions largely through release 
of their granule components. Drugs stabilizing MC mem-
brane preventing degranulation are on the market and used 
predominantly to treat allergic diseases. We next studied 
whether this pharmacological approach could be beneficial 
for DVT prophylaxis. Systemic administration of sodium cro-
moglycate (cromolyn) or ketotifen, MC membrane stabilizers, 
exerted an antithrombotic effect in the DVT model (Figure 5). 
Thrombosis prevalence fell from 71% in saline-treated con-
trols to 31% in animals that received cromolyn (P<0.04) and 
from 80% to 14% in mice that were administered ketotifen 
(P<0.02). Thus, MC membrane stabilization can potentially 
be considered as an anti-DVT approach.
Figure 2. Granule-containing mast 
cells (MCs) are present in the inferior 
vena cava (IVC) wall, and their number 
decreases with thrombosis. A, IVCs 
from wild-type mice were frozen-
sectioned and stained with Toluidine 
blue. MC is indicated by arrow. L, lumen. 
B, MCs were counted in transverse 
sections of intact IVCs (black bar, n=11), 
IVCs after 48 h stenosis with a thrombus 
(gray bar, n=11), and IVCs after 48 h 
stenosis that did not result in thrombus 
formation (patterned bar, n=7).
Figure 3. Mast cell (MC) granule depletion prevents deep vein thrombosis. MC granules were depleted by consecutive daily injections 
of the compound 48/80 as described in the Methods section. Control mice were administered sterile saline. Then, mice were subjected 
to 48 h inferior vena cava stenosis, and thrombi were excised and measured. n=7 in both groups. Presented are thrombus weight 
(A), thrombus length (B), and thrombosis prevalence (C).
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Topical application of compound 48/80 or histamine po-
tentiates thrombosis in WT and induces DVT in KitW-sh mice.
MCs exacerbate DVT apparently by inducing endothelial 
activation and release of WPB. To further explore mecha-
nisms, through which MCs exert their prothrombotic effect, 
we performed topical application of MC secretagogue com-
pound 48/80 or histamine, a potent secretagogue of WPB 
uniquely synthetized and stored in MCs. Six hours of IVC 
stenosis resulted in thrombosis in 2 out of 8 (25%) WT con-
trol mice (Figure 6). In contrast, WT mice locally treated 
Figure 5. Inhibition of mast cell degranulation by membrane stabilization protects against deep vein thrombosis (DVT). A–C, Wild-
type (WT) mice were administered sodium cromoglycate IP (cromolyn, 100 mg/kg body weight, n=17) or sterile saline (n=16) 24 h and 30 
minutes before inferior vena cava stenosis induction. D–F, WT mice were injected with ketotifen IP (25 mg/kg body weight, n=7) or sterile 
saline (n=10) 24 h and 30 minutes before and 24 h after DVT surgery. Thrombus formation was checked 48 h later. Thrombus weight 
(A and D), thrombus length (B and E), and thrombosis prevalence (C and F) are shown.
Figure 4. Mast cells regulate plasma levels of von Willebrand Factor (vWF) and platelet recruitment to the stenosed inferior vena 
cava (IVC) wall. A, Blood was drawn from the retro-orbital plexus of unchallenged wild-type (WT) and KitW-sh mice (n=7–10), stabilized 
with sodium citrate, and plasma levels of vWF were measured. B, Representative composite images of 10 consecutive frames of intravital 
microscopy showing fluorescent platelets adhered to the IVC wall 6 h after stenosis induction. Only mice without a thrombus at this time 
point were used. C, Percent of the area covered by adhered platelets in WT (black bar) and KitW-sh mice 6 h after stenosis application. n=4 
for both groups.
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with compound 48/80 developed thrombus in 80% of cases 
(P<0.03). Histamine-treated WT mice developed a thrombus 
in 87.5% of cases (P<0.02 versus saline-treated animals). 
Interestingly, all KitW-sh animals, normally completely pro-
tected against DVT even at longer time points (48 hours), had 
thrombi after topical application of histamine, indicating that 
histamine can correct DVT defect in MC-deficient mice. Thus, 
it seems that local activation of MCs in WT mice promotes 
DVT, and this effect is likely mediated by histamine release.
We next performed administration of histamine H1 receptor 
(which is expressed on endothelial cells43,44) antagonists, pyril-
amine maleate or cetirizine, to test whether inhibition of hista-
mine effect can inhibit thrombosis. No protective effect of either 
of the substances on DVT was observed (Online Figure VI).
Discussion
Current methods of DVT prophylaxis, targeting clotting fac-
tors, are inevitably accompanied by bleeding complications 
in a certain percent of patients. This is not surprising because 
components of blood coagulation system are involved in nor-
mal hemostasis, and downregulation of their function predict-
ably affects physiological bleeding arrest. We report here (1) a 
novel role of MCs in DVT and (2) an attempt to prevent venous 
thrombosis using an alternative approach—inhibition of MCs, 
which are not directly implicated in hemostasis and therefore 
targeting them is unlikely to cause pathological bleeding.
Venous thrombus formation induced by flow distortion is 
based on endothelial activation, release of WPB components, 
and recruitment of innate immune cells and platelets, which 
precede thrombosis.13,17 Prevention of recruitment of immune 
cell, for example, in P-selectin–deficient mice, or platelets, re-
sults in strong protection against DVT.13,17 Thus, mechanisms 
of DVT in this model include not only blood coagulation but 
also elements of sterile inflammation. MCs contain both in-
hibitors of coagulation, such as heparin and tPA, which could 
be expected to inhibit thrombosis, and proinflammatory me-
diators, such as histamine and tumor necrosis factor-α, which 
could exert a prothrombotic effect given that DVT is an im-
munothrombosis and its mechanisms involve inflammatory 
components.45 This made it initially difficult to predict which 
of the pathways would turn out to be more important for DVT. 
We demonstrate that 2 independent strains of MC-deficient 
mice were completely protected against DVT in the IVC 
stenosis model. Lack of thrombosis in the absence of MCs 
suggests that MCs contain an entity, whose prothrombotic po-
tential outweighs the antithrombotic power of one or several 
other MC components. One potential explanation of the rela-
tive inactivity of MC-derived anticoagulants is that MCs are 
located in the tissue surrounding the IVC, and their released 
granule constituents may reach abluminal part of endothelium 
but not the blood stream. In this scenario, proinflammatory 
mediators can activate endothelium, whereas heparin and tPA 
may not exert their anticoagulant effect. It should be noted 
that a small proportion of WT mice may not produce thrombi 
in this model. This suggests that the prothrombotic activity of 
MCs is not absolute and because of unclear reason might not 
suffice for thrombus formation in certain cases. Also, it should 
be noted that our results have been obtained on a mouse mod-
el, which has substantial differences from the human situation. 
In particular, murine IVC does not contain valves, whereas in 
humans, DVT develops inside venous valves. Also, humans 
have vertical spinal orientation, whereas mice have horizon-
tal one, which means importance of muscle pump in venous 
return of blood to the heart in humans and unimportance of it 
in mice. There are difference also in various aspects of the im-
mune system.46 For example, neutrophils constitute different 
percent of leukocytes in mice in humans,46,47 which might be 
relevant to venous thrombosis as neutrophils support DVT by 
expelling neutrophil extracellular traps.16 Thus, the validity of 
our results for humans remains to be verified in future trans-
lational studies in patients. The availability of MC membrane 
stabilizers on the market makes such studies possible in the 
not too distant future.
Mice used in this study lack MCs because of different 
mutations in c-Kit (CD117), a receptor to stem cell factor. In 
addition to absence of MCs, mutations in c-Kit may lead to 
other abnormalities. For example, homozygous KitW-v mice 
have macrocytic anemia and germ cell developmental defects, 
whereas KitW-sh mutation is accompanied by abnormal vascular 
permeability induced by bee venom phospholipase A2. Other 
Figure 6. Topical application of compound 48/80 or histamine potentiates thrombosis in wild type (WT) and histamine induces 
deep vein thrombosis in KitW-sh mice. WT and KitW-sh mice underwent inferior vena cava (IVC) stenosis. During surgery, a strip of paper 
soaked in saline or solutions of either compound 48/80 (in WT mice only) or histamine (in both WT and KitW-sh mice) was applied to the 
IVC for 10 min immediately after stenosis induction. In 6 h, mice were euthanized, and thrombus formation tested. The groups are: 1, 
WT+saline; 2, WT+48/80; 3, WT+histamine; 4, KitW-sh+saline; and 5, KitW-sh+histamine. Presented are thrombus weight (A), thrombus length 
(B), and thrombosis prevalence (C).
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still unknown MC-unrelated defects also cannot be excluded. 
To rule out alternative explanations of the phenotype in these 
mice, other than lack of MCs, we performed adoptive transfer 
of in vitro differentiated MCs into MC-deficient KitW-sh mice. 
This procedure has been shown to restore pool of MCs in dif-
ferent organs within 2 to 3 months.37,38 Adoptive transfer of 
MCs restored thrombosis in KitW-sh mice. Thus, the antithrom-
botic phenotype results primarily from absence of MCs and 
not from other defect caused by c-Kit mutation. Although en-
graftment of transferred MCs might differ from normal MC 
distribution and pattern of MC pool restoration in the IVC wall 
is unclear, such abnormal engraftment could be a potential ex-
planation in case of lack of the phenotype recovery rather than 
in case of successful restoration of thrombosis by MC infusion.
Connective tissue MCs are usually located near blood ves-
sels.48 The IVC turned out to be no exception as MCs were 
found in its wall in the vicinity to abluminal part of the en-
dothelium. Induction of stenosis, which eventually resulted in 
thrombus formation, was associated with decreased numbers of 
granule-containing (toluidine blue-positive) MCs per section, 
whereas MC quantities remained unchanged after stenosis that 
because of unknown reasons did not lead to thrombosis. This 
result suggests a link between MC function and DVT develop-
ment. It is unclear though whether MCs migrate out of the IVC 
wall or fully degranulate becoming invisible in Toluidine blue 
staining. Disappearance of MCs specifically in thrombosed 
IVCs implies that their released cargo triggers DVT.
In addition to genetic mutations, MCs in mice can be targeted 
pharmacologically. Chronic administration of MC secretagogue, 
compound 48/80, makes MCs temporarily functionally inactive 
because of exhaustion of intracellular pools of mediators.31 A 
similar effect can be achieved by MC membrane stabilizers that 
prevent the liberation of MC granule content.32 We tested both 
approaches, and they protected mice from DVT. In case of com-
pound 48/80, the antithrombotic effect might also be attributed 
to downregulation of coagulation factor VII activation,49 and, 
therefore, in addition to its effect on MCs, the compound may 
suppress also the coagulation cascade. Thrombin generation is 
important for DVT in this model because low-molecular-weight 
heparin prevents thrombosis.17 Partial but significant protection 
by inhibiting MC degranulation is of particular importance be-
cause multiple drugs of this kind are already on the market and 
used for antiallergic purposes. Sodium cromoglycate used as a 
MC stabilizer does not have an antiplatelet effect, as shown by 
platelet function analyzer-100,50 and, therefore, platelet inhibi-
tion as a mechanism of DVT prevention can be ruled out.
Thus, MCs maintain vWF secretion in unchallenged mice 
(Figure 4A) and exacerbate DVT likely by stimulating activa-
tion of the endothelium and promoting WPB release. Failure 
to recruit platelets in the intravital microscopy in mice lack-
ing MCs supports this statement. Platelet recruitment is a 
prerequisite for DVT and is dependent on vWF release from 
WPBs.13,17 The phenotype of MC-deficient animals is simi-
lar to vWF knockout mice: in both KitW-sh and vWF knock-
out mice, platelet accrual at the site of future thrombus is 
decreased. Besides platelets, leukocytes are also recruited to 
the IVC wall after stenosis and facilitate DVT by releasing 
neutrophil extracellular traps.16 Also, MC releasate was able 
to stimulate expression of ICAM-1, a major adhesion receptor 
for leukocytes, on endothelial cells in vitro. Consequently, 
MCs upregulate endothelial activation and liberation of vWF 
and P-selectin from WPBs and by this support DVT.
Interestingly, IVC stenosis is accompanied by elevated 
plasma sP-selectin levels, which can originate from both 
platelets and endothelium. Regardless of sP-selectin origin 
in this particular model, its plasma content is also regulated 
by MCs because in KitW-sh mice no sP-selectin upregulation 
was observed. Plasma sP-selectin is known to promote DVT 
in mice and is a DVT biomarker39,42,51 so that its increase in 
WT mice after IVC stenosis further suggests the similarity be-
tween the animal model and the human disease.
Topical application of MC secretagogue compound 48/80 
stimulated thrombosis, suggesting that it is a MC granule con-
stituent, likely a small molecule that affects endothelium or 
can permeate into blood, which promotes DVT in this model. 
Histamine is the likely candidate for stimulating WPB release. 
It is a potent WPB secretagogue,52 and MCs are a unique source 
of it. Local application of histamine to the IVC accelerated 
thrombosis in WT mice and induced DVT in MC-deficient 
mice. Thus, histamine is able to overcome the effect of MC 
deficiency, suggesting that it is the important constituent of 
MC granules, which may mediate MC prothrombotic effect. 
However, systemic administration of histamine H1 receptor in-
hibitors did not protect mice from DVT. This may be explained 
in several ways. First, histamine may not be a decisive WPB 
component, and the prothrombotic effect of MCs may require 
combined action of ≥2 additional components (eg, tumor necro-
sis factor-α). Second, histamine may act through >1 receptor. 
For example, H2 receptor operates in some vascular beds53 so 
inhibition of only 1 receptor might be insufficient. Third, his-
tamine from MC granules reaches endothelial cells from their 
basal side, and, therefore, its effect may not be fully abolished 
by the receptor inhibitors, which operate at the luminal side. 
Given relatively long time of the experiment (48 hours), insuf-
ficient circulation time of the inhibitors also cannot be ruled out.
If MC absence or suppression protects against thrombosis, 
a question may arise as to why mastocytosis does not lead 
to thrombus formation. For example, no thrombi in the skin 
vessels of urticaria pigmentosa patients have been described. 
The explanation of this phenomenon may be that when the 
number of MCs increases, the ratio between anticoagulants 
(heparin, tPA) and proinflammatory mediators (histamine, tu-
mor necrosis factor-α) released from MCs shifts toward the 
anticoagulants, rendering the resulting phenotype rather nor-
mal or bleeding than prothrombotic.
In conclusion, we have demonstrated that MCs are potent 
regulators of DVT in mice. The effect of MCs is likely to be 
at least partially implemented through release of histamine, 
although other MC granule constituents may contribute as 
well. KitW-sh mice have normal bleeding time, implying that 
temporary switching off MCs should not result in excessive 
bleeding. Thus, MCs may be considered a promising target for 
DVT prevention in humans.
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